The Financial Express3d
Eli Lilly’s Zepbound holds potential to dominate obesity market
Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...
Tirzepatide outpacing Wegovy in the obesity space
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Mint13d
THIS weight-loss drug becomes first to gain approval for treating sleep apnea; details here
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients ...
Ozempic economics: How GLP-1s will disrupt the economy in 2025
A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...
It’s getting harder to claim success with weight reduction drugs
Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.